STOCK TITAN

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Manuel Hidalgo Medina of Guardant Health [GH] received new equity compensation grants on June 18, 2025, consisting of:

  • Stock Options: Granted 6,833 options to buy common stock at an exercise price of $50.57, which vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first. The options expire on June 18, 2035.
  • Restricted Stock Units (RSUs): Awarded 4,203 RSUs that vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first.

This Form 4 filing, submitted by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combined awards suggest continued board engagement and alignment with shareholder interests through both performance-based options and time-vested RSUs.

Il direttore Manuel Hidalgo Medina di Guardant Health [GH] ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, che comprendono:

  • Opzioni su azioni: Concesse 6.833 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di $50,57, che maturano completamente il 18 giugno 2026 o alla prossima assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima. Le opzioni scadono il 18 giugno 2035.
  • Unità azionarie vincolate (RSU): Assegnate 4.203 RSU che maturano completamente il 18 giugno 2026 o alla prossima assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima.

Questa dichiarazione Form 4, presentata dall’avvocato rappresentante John G. Saia il 20 giugno 2025, rappresenta le consuete assegnazioni di compensi azionari per i direttori. Le assegnazioni combinate indicano un impegno continuo del consiglio e un allineamento con gli interessi degli azionisti, attraverso opzioni basate sulle performance e RSU con maturazione temporale.

El director Manuel Hidalgo Medina de Guardant Health [GH] recibió nuevas concesiones de compensación en acciones el 18 de junio de 2025, que consisten en:

  • Opciones sobre acciones: Se otorgaron 6,833 opciones para comprar acciones ordinarias a un precio de ejercicio de $50.57, que se consolidan completamente el 18 de junio de 2026 o en la próxima junta anual de accionistas, lo que ocurra primero. Las opciones expiran el 18 de junio de 2035.
  • Unidades de acciones restringidas (RSU): Se otorgaron 4,203 RSU que se consolidan completamente el 18 de junio de 2026 o en la próxima junta anual de accionistas, lo que ocurra primero.

Esta presentación del Formulario 4, realizada por el apoderado John G. Saia el 20 de junio de 2025, representa concesiones estándar de compensación en acciones para directores. Las concesiones combinadas sugieren un compromiso continuo del consejo y una alineación con los intereses de los accionistas mediante opciones basadas en el rendimiento y RSU con consolidación temporal.

Guardant Health [GH]의 이사 Manuel Hidalgo Medina는 2025년 6월 18일에 다음과 같은 신규 주식 보상 부여를 받았습니다:

  • 스톡 옵션: 행사가 $50.57인 보통주 매수 옵션 6,833주가 부여되었으며, 이는 2026년 6월 18일 또는 다음 연례 주주총회 중 먼저 도래하는 시점에 전면 베스팅됩니다. 옵션 만료일은 2035년 6월 18일입니다.
  • 제한 주식 단위(RSU): 4,203 RSU가 부여되었으며, 2026년 6월 18일 또는 다음 연례 주주총회 중 먼저 도래하는 시점에 전면 베스팅됩니다.

이 Form 4 신고서는 2025년 6월 20일 법정대리인 John G. Saia에 의해 제출되었으며, 표준 이사 보상 주식 부여를 나타냅니다. 이 결합된 보상은 성과 기반 옵션과 시간에 따라 베스팅되는 RSU를 통해 이사회의 지속적인 참여와 주주 이익과의 일치를 시사합니다.

Le directeur Manuel Hidalgo Medina de Guardant Health [GH] a reçu de nouvelles attributions de rémunération en actions le 18 juin 2025, comprenant :

  • Options d'achat d'actions : 6 833 options ont été attribuées pour acheter des actions ordinaires à un prix d'exercice de 50,57 $, qui deviennent entièrement acquises le 18 juin 2026 ou lors de la prochaine assemblée annuelle des actionnaires, selon la première éventualité. Les options expirent le 18 juin 2035.
  • Unités d'actions restreintes (RSU) : 4 203 RSU ont été attribuées et deviennent entièrement acquises le 18 juin 2026 ou lors de la prochaine assemblée annuelle des actionnaires, selon la première éventualité.

Ce dépôt du formulaire 4, soumis par le mandataire John G. Saia le 20 juin 2025, représente des attributions standard de rémunération en actions pour les administrateurs. Ces attributions combinées suggèrent un engagement continu du conseil d'administration et un alignement avec les intérêts des actionnaires à travers des options basées sur la performance et des RSU acquises dans le temps.

Direktor Manuel Hidalgo Medina von Guardant Health [GH] erhielt am 18. Juni 2025 neue Aktienvergütungszuteilungen, bestehend aus:

  • Aktienoptionen: Gewährt wurden 6.833 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 50,57 USD, die vollständig am 18. Juni 2026 oder auf der nächsten jährlichen Hauptversammlung der Aktionäre, je nachdem, was zuerst eintritt, vesten. Die Optionen verfallen am 18. Juni 2035.
  • Restricted Stock Units (RSUs): 4.203 RSUs wurden zugeteilt, die vollständig am 18. Juni 2026 oder auf der nächsten jährlichen Hauptversammlung der Aktionäre, je nachdem, was zuerst eintritt, vesten.

Diese Form 4-Einreichung, eingereicht vom Bevollmächtigten John G. Saia am 20. Juni 2025, stellt standardmäßige Aktienvergütungszuteilungen für Direktoren dar. Die kombinierten Zuteilungen deuten auf ein fortgesetztes Engagement im Vorstand und eine Ausrichtung an den Interessen der Aktionäre durch leistungsabhängige Optionen und zeitlich vestende RSUs hin.

Positive
  • None.
Negative
  • None.

Il direttore Manuel Hidalgo Medina di Guardant Health [GH] ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, che comprendono:

  • Opzioni su azioni: Concesse 6.833 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di $50,57, che maturano completamente il 18 giugno 2026 o alla prossima assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima. Le opzioni scadono il 18 giugno 2035.
  • Unità azionarie vincolate (RSU): Assegnate 4.203 RSU che maturano completamente il 18 giugno 2026 o alla prossima assemblea annuale degli azionisti, a seconda di quale evento si verifichi prima.

Questa dichiarazione Form 4, presentata dall’avvocato rappresentante John G. Saia il 20 giugno 2025, rappresenta le consuete assegnazioni di compensi azionari per i direttori. Le assegnazioni combinate indicano un impegno continuo del consiglio e un allineamento con gli interessi degli azionisti, attraverso opzioni basate sulle performance e RSU con maturazione temporale.

El director Manuel Hidalgo Medina de Guardant Health [GH] recibió nuevas concesiones de compensación en acciones el 18 de junio de 2025, que consisten en:

  • Opciones sobre acciones: Se otorgaron 6,833 opciones para comprar acciones ordinarias a un precio de ejercicio de $50.57, que se consolidan completamente el 18 de junio de 2026 o en la próxima junta anual de accionistas, lo que ocurra primero. Las opciones expiran el 18 de junio de 2035.
  • Unidades de acciones restringidas (RSU): Se otorgaron 4,203 RSU que se consolidan completamente el 18 de junio de 2026 o en la próxima junta anual de accionistas, lo que ocurra primero.

Esta presentación del Formulario 4, realizada por el apoderado John G. Saia el 20 de junio de 2025, representa concesiones estándar de compensación en acciones para directores. Las concesiones combinadas sugieren un compromiso continuo del consejo y una alineación con los intereses de los accionistas mediante opciones basadas en el rendimiento y RSU con consolidación temporal.

Guardant Health [GH]의 이사 Manuel Hidalgo Medina는 2025년 6월 18일에 다음과 같은 신규 주식 보상 부여를 받았습니다:

  • 스톡 옵션: 행사가 $50.57인 보통주 매수 옵션 6,833주가 부여되었으며, 이는 2026년 6월 18일 또는 다음 연례 주주총회 중 먼저 도래하는 시점에 전면 베스팅됩니다. 옵션 만료일은 2035년 6월 18일입니다.
  • 제한 주식 단위(RSU): 4,203 RSU가 부여되었으며, 2026년 6월 18일 또는 다음 연례 주주총회 중 먼저 도래하는 시점에 전면 베스팅됩니다.

이 Form 4 신고서는 2025년 6월 20일 법정대리인 John G. Saia에 의해 제출되었으며, 표준 이사 보상 주식 부여를 나타냅니다. 이 결합된 보상은 성과 기반 옵션과 시간에 따라 베스팅되는 RSU를 통해 이사회의 지속적인 참여와 주주 이익과의 일치를 시사합니다.

Le directeur Manuel Hidalgo Medina de Guardant Health [GH] a reçu de nouvelles attributions de rémunération en actions le 18 juin 2025, comprenant :

  • Options d'achat d'actions : 6 833 options ont été attribuées pour acheter des actions ordinaires à un prix d'exercice de 50,57 $, qui deviennent entièrement acquises le 18 juin 2026 ou lors de la prochaine assemblée annuelle des actionnaires, selon la première éventualité. Les options expirent le 18 juin 2035.
  • Unités d'actions restreintes (RSU) : 4 203 RSU ont été attribuées et deviennent entièrement acquises le 18 juin 2026 ou lors de la prochaine assemblée annuelle des actionnaires, selon la première éventualité.

Ce dépôt du formulaire 4, soumis par le mandataire John G. Saia le 20 juin 2025, représente des attributions standard de rémunération en actions pour les administrateurs. Ces attributions combinées suggèrent un engagement continu du conseil d'administration et un alignement avec les intérêts des actionnaires à travers des options basées sur la performance et des RSU acquises dans le temps.

Direktor Manuel Hidalgo Medina von Guardant Health [GH] erhielt am 18. Juni 2025 neue Aktienvergütungszuteilungen, bestehend aus:

  • Aktienoptionen: Gewährt wurden 6.833 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 50,57 USD, die vollständig am 18. Juni 2026 oder auf der nächsten jährlichen Hauptversammlung der Aktionäre, je nachdem, was zuerst eintritt, vesten. Die Optionen verfallen am 18. Juni 2035.
  • Restricted Stock Units (RSUs): 4.203 RSUs wurden zugeteilt, die vollständig am 18. Juni 2026 oder auf der nächsten jährlichen Hauptversammlung der Aktionäre, je nachdem, was zuerst eintritt, vesten.

Diese Form 4-Einreichung, eingereicht vom Bevollmächtigten John G. Saia am 20. Juni 2025, stellt standardmäßige Aktienvergütungszuteilungen für Direktoren dar. Die kombinierten Zuteilungen deuten auf ein fortgesetztes Engagement im Vorstand und eine Ausrichtung an den Interessen der Aktionäre durch leistungsabhängige Optionen und zeitlich vestende RSUs hin.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hidalgo Medina Manuel

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $50.57 06/18/2025 A 6,833 (1) 06/18/2035 Common Stock 6,833 $0 6,833 D
Restricted Stock Units $0 06/18/2025 A 4,203 (2) (3) Common Stock 4,203 $0 4,203 D
Explanation of Responses:
1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
2. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did GH director Manuel Hidalgo Medina receive on June 18, 2025?

Manuel Hidalgo Medina received 6,833 stock options with an exercise price of $50.57. These options will fully vest on June 18, 2026 (one-year anniversary) or the date of the next annual stockholders meeting, whichever comes earlier. The options expire on June 18, 2035.

How many Restricted Stock Units (RSUs) were granted to GH's director Hidalgo Medina?

Manuel Hidalgo Medina was granted 4,203 Restricted Stock Units (RSUs) on June 18, 2025. These RSUs will vest in full on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is the vesting schedule for GH director Hidalgo Medina's June 2025 equity grants?

Both the stock options and RSUs granted to Hidalgo Medina follow the same vesting schedule: they vest 100% on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever comes first.

What is the total value of equity compensation awarded to GH director Manuel Hidalgo Medina in June 2025?

The Form 4 shows that Hidalgo Medina received two equity awards: 6,833 stock options with a strike price of $50.57 and 4,203 Restricted Stock Units (RSUs) with a $0 exercise price. The RSUs represent direct share equivalents, while the options' value would depend on GH's stock price appreciation above $50.57.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

6.01B
118.13M
4.71%
98.48%
6.4%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO